Biotargets of Cancer in Current Clinical Practice by Mauro BolognaBiotargets of Cancer in Current Clinical Practice by Mauro Bologna

Biotargets of Cancer in Current Clinical Practice

EditorMauro Bologna

Hardcover | April 5, 2012

Pricing and Purchase Info

$395.12 online 
$427.95 list price save 7%
Earn 1976 plum® points
Quantity:

In stock online

Ships free on orders over $25

Not available in stores

about

Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets of innovative therapies. The volume includes for each major cancer type, a comprehensive although concise discussion of epidemiology, affirmed and innovative biomarkers for diagnosis, and descriptions of the relevant genes for prognosis and (individualized) therapy through biotarget-specific new molecular treatments, with the latest information on the validation status of each novel biomarker. Individual chapters are dedicated to the major cancer types, plus a special chapter on metastasis. The present debate on patentability of genetic information applied to diagnostics and therapeutics of cancer is also discussed.
Mauro Bologna, MD University of L'Aquila, L'Aquila, Italy
Loading
Title:Biotargets of Cancer in Current Clinical PracticeFormat:HardcoverDimensions:579 pagesPublished:April 5, 2012Publisher:Humana PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:161779614X

ISBN - 13:9781617796142

Look for similar items by category:

Reviews

Table of Contents

Ch. 1- Central Nervous System Tumors Paolo Aloisi  Francesco Martella Davide Cerone Giampiero Porzio Ch. 2- Head and Neck Tumors Keith D. Hunter Robert BoltCh. 3- Thyroid Cancer Laura D. Locati  Angela Greco Maria Grazia Borrello  Maria Luisa Carcangiu Paolo Bossi  Roberta Granata  Lisa LicitraCh. 4- Targeted Therapies for Non-Small Cell Lung Cancer Giulio Metro Lucio CrinòCh. 5- Non-Hodgkin Lymphomas Roberta Zappasodi Massimo Di NicolaCh. 6- Leukemias Lia Ginaldi   Massimo De Martinis Ch. 7- Breast Cancer Nadia Rucci Luca Ventura Anna TetiCh. 8- Esophago-Gastric Cancer Alex M. Reece-Smith Simon L. Parsons  Sue A. Watson Ch. 9- Colorectal Cancer David Church Rachel Midgley David KerrCh. 10- Hepatocellular Carcinoma Yasunori Minami  Masatoshi KudoCh. 11- Biomarkers for Prognosis and Molecularly Targeted Therapy in Renal Cell Carcinoma Laura S. SchmidtCh. 12- Bladder Cancer Andrea Tubaro Daniele Santini Cosimo De Nunzio Alice Zoccoli Michele IulianoCh. 13- Biomarkers in Prostate cancer Mauro Bologna Carlo VicentiniCh. 14- Ovarian Cancer Jessica Wangui Oribabor  Allison Ambrosio  Cesar M. Castro Michael J. BirrerCh. 15- Uterine Cancer: The Influence of Genetics and Environment on Cell Cycling Pathways in Cancer Annekathryn Goodman Leslie S. Bradford Leslie A. GarrettCh. 16- Biotargets in Sarcomas: The Past, Present and a Look into the Future Vivek Subbiah Razelle KurzrockCh. 17- Melanoma and other skin cancers Kim H.T. Paraiso Jobin K. John Keiran S.M. SmalleyCh. 18- Molecular pathology of cancer metastasis: suggestions for future therapy Adriano Angelucci Edoardo AlesseCh. 19- Current and future developments in cancer therapy research: miRNAs as new promising targets or tools Marilena V. Iorio Patrizia Casalini Claudia Piovan Luca Braccioli Elda Tagliabue

Editorial Reviews

From the reviews:"In this book on clinically significant biotargets in cancer research, every organ system is thoroughly represented with adequate overviews and precise details of the biotargets. . the book is intended specifically for clinicians in the field, including medical students, residents, pathologists, and oncologists. . This is a well-written book that attempts to provide a wide spectrum of current scientific information about the clinical management of oncologic patients based on molecular aspects. . this book achieves its objectives while remaining easy to read." (Natalie Webster, Doody's Review Service, October, 2012)